Astragaloside IV attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation
Conclusion:AS-IV alleviated renal tubule interstitial inflammation and tubule epithelial cell apoptosis in DKD rats by inhibiting CD36-mediated lipid accumulation and NLRP3 inflammasome activation. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 20, 2024 Category: Drugs & Pharmacology Source Type: research
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP
Clin Pharmacol Ther. 2024 Mar 17. doi: 10.1002/cpt.3236. Online ahead of print.ABSTRACTIn a genome-wide association study of atorvastatin pharmacokinetics in 158 healthy volunteers, the SLCO1B1 c.521T>C (rs4149056) variant associated with increased area under the plasma concentration-time curve from time zero to infinity (AUC0-∞ ) of atorvastatin (P = 1.2 × 10-10 ), 2-hydroxy atorvastatin (P = 4.0 × 10-8 ), and 4-hydroxy atorvastatin (P = 2.9 × 10-8 ). An intronic LPP variant, rs1975991, associated with reduced atorvastatin lactone AUC0-∞ (P = 3.8 × 10-8 ). Three UGT1A variants linked with UGT1A3*2 associated wi...
Source: Clinical Pharmacology and Therapeutics - March 17, 2024 Category: Drugs & Pharmacology Authors: Anssi J H Mykk änen E Katriina Tarkiainen Suvi Taskinen Mikko Neuvonen Maria Paile-Hyv ärinen Tuomas O Lilius Tuija Tapaninen Kathrin Klein Matthias Schwab Janne T Backman Aleksi Tornio Mikko Niemi Source Type: research
Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH)
CONCLUSIONS: If compared to placebo, the PCSK9 inhibitor evolocumab combined with statins resulted in a greater decrease in LDL-C and plaque neovascularization in Chinese patients with PCAD.PMID:38493669 | DOI:10.1016/j.atherosclerosis.2024.117471 (Source: Atherosclerosis)
Source: Atherosclerosis - March 17, 2024 Category: Cardiology Authors: Yanyan Han Ling Ren Xiang Fei Jingjing Wang Tao Chen Jun Guo Qi Wang Source Type: research
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP
Clin Pharmacol Ther. 2024 Mar 17. doi: 10.1002/cpt.3236. Online ahead of print.ABSTRACTIn a genome-wide association study of atorvastatin pharmacokinetics in 158 healthy volunteers, the SLCO1B1 c.521T>C (rs4149056) variant associated with increased area under the plasma concentration-time curve from time zero to infinity (AUC0-∞ ) of atorvastatin (P = 1.2 × 10-10 ), 2-hydroxy atorvastatin (P = 4.0 × 10-8 ), and 4-hydroxy atorvastatin (P = 2.9 × 10-8 ). An intronic LPP variant, rs1975991, associated with reduced atorvastatin lactone AUC0-∞ (P = 3.8 × 10-8 ). Three UGT1A variants linked with UGT1A3*2 associated wi...
Source: Clinical Pharmacology and Therapeutics - March 17, 2024 Category: Drugs & Pharmacology Authors: Anssi J H Mykk änen E Katriina Tarkiainen Suvi Taskinen Mikko Neuvonen Maria Paile-Hyv ärinen Tuomas O Lilius Tuija Tapaninen Kathrin Klein Matthias Schwab Janne T Backman Aleksi Tornio Mikko Niemi Source Type: research
Aldo-keto reductase-7A2 protects against atorvastatin-induced hepatotoxicity via Nrf2 activation
This study is, therefore, carried out to investigate the roles of anti-oxidant pathways and enzymes in protection against ATO-induced hepatotoxicity. Here we show that in ATO-challenged HepG2 cells, the expression levels of transcription factor NFE2L2/Nrf2 (nuclear factor erythroid 2 p45-related factor 2) are significantly upregulated. When Nrf2 is pharmacologically inhibited or genetically inactivated, ATO-induced cytotoxicity is significantly aggravated. Aldo-keto reductase-7A (AKR7A) enzymes, transcriptionally regulated by Nrf2, are important for bioactivation and biodetoxification. Here, we reveal that in response to A...
Source: Chemico-Biological Interactions - March 14, 2024 Category: Molecular Biology Authors: Dan Li Jiajin Chen Fei Zhou Wenhe Zhang Hongyu Chen Source Type: research
Aldo-keto reductase-7A2 protects against atorvastatin-induced hepatotoxicity via Nrf2 activation
This study is, therefore, carried out to investigate the roles of anti-oxidant pathways and enzymes in protection against ATO-induced hepatotoxicity. Here we show that in ATO-challenged HepG2 cells, the expression levels of transcription factor NFE2L2/Nrf2 (nuclear factor erythroid 2 p45-related factor 2) are significantly upregulated. When Nrf2 is pharmacologically inhibited or genetically inactivated, ATO-induced cytotoxicity is significantly aggravated. Aldo-keto reductase-7A (AKR7A) enzymes, transcriptionally regulated by Nrf2, are important for bioactivation and biodetoxification. Here, we reveal that in response to A...
Source: Chemico-Biological Interactions - March 14, 2024 Category: Molecular Biology Authors: Dan Li Jiajin Chen Fei Zhou Wenhe Zhang Hongyu Chen Source Type: research
Recurrent syncope due to ischemia with non-obstructive coronary artery disease: a case report
ConclusionThis study highlights the importance of considering ischemia with non-obstructive coronary artery disease as a potential cause of syncope in the differential diagnosis. It emphasizes the need for early diagnosis of ischemia with non-obstructive coronary artery disease to facilitate more effective management strategies. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - March 12, 2024 Category: General Medicine Source Type: research
Atorvastatin's Therapeutic Potential in Atherosclerosis: Inhibiting TGF-beta-Induced Proteoglycan Glycosaminoglycan Chain Elongation through ROS-ERK1/2-Smad2L Signaling Pathway Modulation in Vascular Smooth Muscle Cells
CONCLUSION: These data suggest that atorvastatin demonstrates anti-atherogenic properties through the modulation of the ROS-ERK1/2-Smad2L signaling pathway. This provides valuable insight into the potential mechanisms by which atorvastatin exerts its pleiotropic effects against atherosclerosis.PMID:38459733 | DOI:10.22074/cellj.2023.2010482.1397 (Source: Atherosclerosis)
Source: Atherosclerosis - March 9, 2024 Category: Cardiology Authors: Hossein Ghaderi-Zefrehi Ghorban Mohammadzadeh Mojtaba Rashidi Maryam Adelipour Hossein Babaahmadi Rezaei Source Type: research
Atorvastatin's Therapeutic Potential in Atherosclerosis: Inhibiting TGF-beta-Induced Proteoglycan Glycosaminoglycan Chain Elongation through ROS-ERK1/2-Smad2L Signaling Pathway Modulation in Vascular Smooth Muscle Cells
CONCLUSION: These data suggest that atorvastatin demonstrates anti-atherogenic properties through the modulation of the ROS-ERK1/2-Smad2L signaling pathway. This provides valuable insight into the potential mechanisms by which atorvastatin exerts its pleiotropic effects against atherosclerosis.PMID:38459733 | PMC:PMC10924836 | DOI:10.22074/cellj.2023.2010482.1397 (Source: Atherosclerosis)
Source: Atherosclerosis - March 9, 2024 Category: Cardiology Authors: Hossein Ghaderi-Zefrehi Ghorban Mohammadzadeh Mojtaba Rashidi Maryam Adelipour Hossein Babaahmadi Rezaei Source Type: research
Changes in the content of emerging pollutants and potentially hazardous substances during vermi/composting of a mixture of sewage sludge and moulded pulp
This study deals with composting and vermicomposting of pre-composted mixtures of two different kinds of sewage sludge blended with moulded pulp in an operating composting plant. Of the total number and concentration of pollutants detected in individual piles, a large percentage of them were reduced by the composting process. The composting 2 process resulted in the greatest reduction in contaminating substances--a total of 19 substances by 4.39-90.4%. Some pharmaceuticals accumulated in earthworm bodies during vermicomposting; a total of 11 substances were detected. Atorvastatin showed the highest percentage reduction in ...
Source: Environmental Pollution - March 8, 2024 Category: Environmental Health Authors: M Hr čka T H řebečková A Han č Source Type: research
A novel mouse model of familial combined hyperlipidemia and atherosclerosis
In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg-1·d-1) and fenofibrate (100 mg·kg-1·d-1). HCD-treated hApoC3-Tg mice demonstrated elevated levels of serum TG, total cholesterol (TC) and low density lipoprotein-cho...
Source: Atherosclerosis - March 8, 2024 Category: Cardiology Authors: Mei-Jie Chen Yi-Tong Xu Lu Sun Zhi-Hua Wang Peter J Little Li Wang Xun-de Xian Jian-Ping Weng Suo-Wen Xu Source Type: research
A novel mouse model of familial combined hyperlipidemia and atherosclerosis
In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg-1·d-1) and fenofibrate (100 mg·kg-1·d-1). HCD-treated hApoC3-Tg mice demonstrated elevated levels of serum TG, total cholesterol (TC) and low density lipoprotein-cho...
Source: Acta Pharmacologica Sinica - March 8, 2024 Category: Drugs & Pharmacology Authors: Mei-Jie Chen Yi-Tong Xu Lu Sun Zhi-Hua Wang Peter J Little Li Wang Xun-de Xian Jian-Ping Weng Suo-Wen Xu Source Type: research
Changes in the content of emerging pollutants and potentially hazardous substances during vermi/composting of a mixture of sewage sludge and moulded pulp
This study deals with composting and vermicomposting of pre-composted mixtures of two different kinds of sewage sludge blended with moulded pulp in an operating composting plant. Of the total number and concentration of pollutants detected in individual piles, a large percentage of them were reduced by the composting process. The composting 2 process resulted in the greatest reduction in contaminating substances--a total of 19 substances by 4.39-90.4%. Some pharmaceuticals accumulated in earthworm bodies during vermicomposting; a total of 11 substances were detected. Atorvastatin showed the highest percentage reduction in ...
Source: Environmental Pollution - March 8, 2024 Category: Environmental Health Authors: M Hr čka T H řebečková A Han č Source Type: research
A novel mouse model of familial combined hyperlipidemia and atherosclerosis
In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg-1·d-1) and fenofibrate (100 mg·kg-1·d-1). HCD-treated hApoC3-Tg mice demonstrated elevated levels of serum TG, total cholesterol (TC) and low density lipoprotein-cho...
Source: Acta Pharmacologica Sinica - March 8, 2024 Category: Drugs & Pharmacology Authors: Mei-Jie Chen Yi-Tong Xu Lu Sun Zhi-Hua Wang Peter J Little Li Wang Xun-de Xian Jian-Ping Weng Suo-Wen Xu Source Type: research
A novel mouse model of familial combined hyperlipidemia and atherosclerosis
In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg-1·d-1) and fenofibrate (100 mg·kg-1·d-1). HCD-treated hApoC3-Tg mice demonstrated elevated levels of serum TG, total cholesterol (TC) and low density lipoprotein-cho...
Source: Acta Pharmacologica Sinica - March 8, 2024 Category: Drugs & Pharmacology Authors: Mei-Jie Chen Yi-Tong Xu Lu Sun Zhi-Hua Wang Peter J Little Li Wang Xun-de Xian Jian-Ping Weng Suo-Wen Xu Source Type: research
